Lung Cancer Dispatch
4.6K views | +0 today
Follow
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Suggested by Cancer Commons
Scoop.it!

MSC Lung Cancer Test Offers Fewer False Positives, Early Detection

MSC Lung Cancer Test Offers Fewer False Positives, Early Detection | Lung Cancer Dispatch | Scoop.it

Low-dose computed tomography (CT) scans are the currently recommended screening method for lung cancer in heavy smokers. However, these scans produce many false positives (identifying suspicious lung nodules when no cancer is actually present), needlessly exposing numerous people to the costs and risks of invasive follow-up procedures. Now, a large study has shown that a simple blood test may complement CT scans to reduce the false positive rate in lung cancer screening. The microRNA signature classifier (MSC) Lung Cancer assay measures the expression levels of several molecules called microRNAs to classify patients as low, intermediate, and high risk. In a trial of over 4,000 current or former smokers, the MSC Lung Cancer assay detected the vast majority of all lung cancers accurately, but produced a low rate of false positives. Moreover, the test detected some cancers up to 2 years before the CT scans.

Cancer Commons's insight:

Medical News Today  |  Jan 15, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

New Clinical Trial Focuses on Cancer Patients Without Known Tumor Mutations

New Clinical Trial Focuses on Cancer Patients Without Known Tumor Mutations | Lung Cancer Dispatch | Scoop.it

Increasingly, targeted therapies are becoming available for patients whose cancers have mutations in certain 'driver' genes that are known to be involved in cancer growth. However, most cancer patients have tumors without these mutations or other changes in their DNA. These patients will be the focus of the new WINTHER clinical trial. The study will compare biopsy samples of the patients’ tumors with healthy tissue samples to see how much they differ. This information, along with examinations of other molecules involved in gene expression called RNA and microRNA, will be used to select the existing cancer treatment most likely to benefit the patient based on a novel scoring system.

Cancer Commons's insight:

Healio | Jul 12, 2013

more...
Cancer Commons's curator insight, July 16, 2013 5:02 PM

Healio | Jul 12, 2013

Cancer Commons's curator insight, July 16, 2013 5:02 PM

Healio | Jul 12, 2013

Cancer Commons's curator insight, July 16, 2013 5:03 PM

Healio | Jul 12, 2013

Suggested by Cancer Commons
Scoop.it!

New Biomarker May Allow Development of Less Invasive Test for Lung Cancer, New Lung Cancer Treatments

New Biomarker May Allow Development of Less Invasive Test for Lung Cancer, New Lung Cancer Treatments | Lung Cancer Dispatch | Scoop.it

MicroRNAs are small molecules that turn down or switch off other genes and influence a wide range of processes in cells throughout the body. Researchers discovered that the microRNA 4423 (miR-4423) is found in higher levels in cells lining the airways of the lungs than in other parts of the body. But, levels of miR-4423 are lower in lung tumors and in otherwise normal-appearing airway cells of people with lung cancer. Because miR-4423 is found on the surface of the airways, measuring miR-4423 levels may serve as a relatively noninvasive test for lung cancer. Adding miR-4423 back inhibited the growth of lung cancer cells in cell cultures and decreased the size of lung cancer tumors implanted into mice. Increasing miR-4423 levels may therefore also form the basis of future lung cancer treatments.

Cancer Commons's insight:

ScienceDaily | Oct 25, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Variations in Certain Genes May Predict Clinical Outcomes in Early-Stage Lung Cancer

Early-stage non-small cell lung cancer (NSCLC) is usually treated with surgical removal of the tumor. However, in up to 50% of patients, the cancer will return within 5 years. A study of genetic variations that affect the function of microRNAs (small molecules involved in gene expression) found that several of them, including variations in the FAS, FZD4, SP1, and DROSHA genes, were associated with higher or lower probabilities of cancer recurrence and survival. Tests for such microRNA-related genetic variations may eventually help identify high-risk, early-stage NSCLC patients who would benefit from additional treatment after surgery.

Cancer Commons's insight:

Cancer Research | Feb 1, 2013

more...
No comment yet.